Log in

AEterna Zentaris Stock Price, Forecast & Analysis (NASDAQ:AEZS)

$0.99
-0.02 (-1.98 %)
(As of 11/16/2019 08:00 AM ET)
Today's Range
$0.97
Now: $0.99
$1.02
50-Day Range
$0.85
MA: $1.01
$1.11
52-Week Range
$0.81
Now: $0.99
$5.57
Volume43,400 shs
Average Volume152,220 shs
Market Capitalization$19.76 million
P/E Ratio3.96
Dividend YieldN/A
Beta1.11
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AEZS
CUSIPN/A
Phone843-900-3201

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.90 million
Cash Flow$0.22 per share
Book Value($0.11) per share

Profitability

Net Income$4.19 million
Net Margins-529.57%

Miscellaneous

EmployeesN/A
Market Cap$19.76 million
Next Earnings Date3/24/2020 (Estimated)
OptionableOptionable

Receive AEZS News and Ratings via Email

Sign-up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter.


AEterna Zentaris (NASDAQ:AEZS) Frequently Asked Questions

What is AEterna Zentaris' stock symbol?

AEterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."

How were AEterna Zentaris' earnings last quarter?

AEterna Zentaris Inc. (NASDAQ:AEZS) announced its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.15. The biopharmaceutical company had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.24 million. AEterna Zentaris had a negative net margin of 529.57% and a negative return on equity of 1,428.66%. View AEterna Zentaris' Earnings History.

When is AEterna Zentaris' next earnings date?

AEterna Zentaris is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for AEterna Zentaris.

What price target have analysts set for AEZS?

2 brokers have issued 1-year target prices for AEterna Zentaris' stock. Their forecasts range from $2.00 to $3.00. On average, they anticipate AEterna Zentaris' share price to reach $2.50 in the next year. This suggests a possible upside of 152.5% from the stock's current price. View Analyst Price Targets for AEterna Zentaris.

What is the consensus analysts' recommendation for AEterna Zentaris?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AEterna Zentaris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AEterna Zentaris.

What are Wall Street analysts saying about AEterna Zentaris stock?

Here are some recent quotes from research analysts about AEterna Zentaris stock:
  • 1. According to Zacks Investment Research, "AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. " (11/5/2019)
  • 2. HC Wainwright analysts commented, "We maintain our Buy rating of AEZS and our 12-month price target of $5.50 per share. We derive our price target using a risk- adjusted net present value analysis of potential US and EU royalties, discounted at 18%, to reach a total rNPV of $66M for the royalty streams." (8/15/2019)

Has AEterna Zentaris been receiving favorable news coverage?

News headlines about AEZS stock have trended extremely negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. AEterna Zentaris earned a media sentiment score of -5.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for AEterna Zentaris.

Are investors shorting AEterna Zentaris?

AEterna Zentaris saw a decrease in short interest in the month of October. As of October 15th, there was short interest totalling 348,900 shares, a decrease of 14.2% from the September 15th total of 406,500 shares. Based on an average trading volume of 148,100 shares, the short-interest ratio is currently 2.4 days. Currently, 2.1% of the shares of the stock are sold short. View AEterna Zentaris' Current Options Chain.

Who are some of AEterna Zentaris' key competitors?

What other stocks do shareholders of AEterna Zentaris own?

Who are AEterna Zentaris' key executives?

AEterna Zentaris' management team includes the folowing people:
  • Mr. Michael V. Ward, Pres & CEO (Age 62)
  • Ms. Leslie Auld, Sr. VP & CFO
  • Mr. Brian Garrison, Sr. VP of Global Corp. Operations & Corp. Devel.
  • Dr. Nicola Ammer, Chief Medical Officer & VP of Clinical Devel.
  • Mr. Olaf Althaus, GM & MD

How do I buy shares of AEterna Zentaris?

Shares of AEZS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AEterna Zentaris' stock price today?

One share of AEZS stock can currently be purchased for approximately $0.99.

How big of a company is AEterna Zentaris?

AEterna Zentaris has a market capitalization of $19.76 million and generates $26.90 million in revenue each year. The biopharmaceutical company earns $4.19 million in net income (profit) each year or $0.25 on an earnings per share basis. View Additional Information About AEterna Zentaris.

What is AEterna Zentaris' official website?

The official website for AEterna Zentaris is http://www.aezsinc.com/.

How can I contact AEterna Zentaris?

AEterna Zentaris' mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The biopharmaceutical company can be reached via phone at 843-900-3201 or via email at [email protected]


MarketBeat Community Rating for AEterna Zentaris (NASDAQ AEZS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  379 (Vote Outperform)
Underperform Votes:  269 (Vote Underperform)
Total Votes:  648
MarketBeat's community ratings are surveys of what our community members think about AEterna Zentaris and other stocks. Vote "Outperform" if you believe AEZS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AEZS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2019 by MarketBeat.com Staff

Featured Article: Is the QQQ ETF safe?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel